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Abstract Oxidation of low density lipoprotein (LDL) by
glucose-derived radicals may play a role in the aetiology of
atherosclerosis in diabetes. Salicylate was shown to scavenge
certain radicals. In the present study, aspirin, salicylate and its
metabolites 2,5- and 2,3-dihydroxybenzoic acid (DHBA) were
tested for their ability to impair LDL oxidation by glucose. Only
the DHBA derivatives, when present during LDL modification,
inhibited LDL oxidation and the increase in endothelial tissue
factor synthesis induced by glucose oxidised LDL. The LDL
glycation reaction was not affected by DHBA. The antioxidative
action of DHBA may be attributed to free radical scavenging
and/or chelation of transition metal ions catalysing glucose
autoxidation.
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1. Introduction
It has been assumed that oxidative stress contributes to the
development of the diabetic complications [1]. In this respect,
lower levels of antioxidants like ascorbic acid and vitamin E
have been reported to occur in diabetes [2,3]. Elevated levels
of glycoxidation and lipoxidation products have been found
in plasma and tissue proteins in diabetes [4^7]. Insulin treat-
ment of type 1 diabetes patients reduced plasma hydroperox-
ides and, thus, reactive oxygen species [8].
The onset and progression of atherosclerosis is accelerated
in diabetes [9]. Low density lipoprotein (LDL) oxidative
(atherogenic) modi¢cation has been found to play a pivotal
role in early stage atherogenesis [10^12]. As an in vitro model
of protein alterations in diabetes, glucose treatment of LDL
causes peroxidation (and glycation) of the lipoprotein [13^15].
Glucose autoxidation results in the generation of several rad-
ical species [16,17]. Salicylate has been shown to scavenge
hydroxyl radicals [18,19] and we have recently shown that
salicylate and gentisic acid (2,5-DHBA) the ¢rst and second
line aspirin metabolites impaired superoxide/nitric oxide rad-
ical-initiated LDL oxidation [20].
Thus the aim of this study was to assess the potential of
aspirin and its metabolites to act as inhibitors against the
battery of glucose-derived radicals mediating atherogenic
modi¢cation of LDL, a property that might have implications
in preventing diabetic complications.
2. Materials and methods
Aspirin (acetylsalicylic acid), salicylic acid (2-hydroxybenzoic acid),
2,3-dihydroxybenzoic acid (2,3-DHBA), 2,5-dihydroxybenzoic acid
(2,5-DHBA, gentisic acid), bovine serum albumin and lipopolysaccha-
ride (Escherichia coli 055:B5) were from Sigma Chem. Co. and
D-glucose monohydrate from Merck. All other chemicals used were
of analytical grade.
2.1. LDL isolation
LDL was isolated from EDTA^plasma of healthy male volunteers
by ultracentrifugation as reported previously [21]. The ¢nal prepara-
tion was dialysed against 150 mmol/l NaCl containing 0.1 mmol/l
EDTA and ¢lter-sterilised.
2.2. LDL oxidation by glucose
Prior to LDL oxidation, the lipoprotein was equilibrated in 0.1 mol/l
phosphate bu¡er pH 7.4 using Sephadex G-25 chromatography (PD-
10 columns, Pharmacia). LDL (1 mg/ml) was incubated in the pres-
ence of 200 mmol/l D-glucose [7,15] up to 9 days at 37‡C under sterile
conditions.
2.3. LDL glycation
LDL (1 mg/ml) was incubated in 0.1 mol/l phosphate bu¡er, pH
7.4, in the presence of 20 mmol/l D-glucose and 10 WCi/ml
[U-14C]glucose (ICN Biomedicals, speci¢c activity 316 mCi/mmol) at
37‡C for 6 days. Lipoproteins were precipitated by the addition of
TCA to a ¢nal concentration of 5%. The pellet was washed in 5%
TCA and ¢nally dissolved in formic acid before scintillation counting
[14].
2.4. Cell culture
Endothelial cells (HUVEC) were isolated from human umbilical
veins and maintained in culture as reported previously [22].
2.5. Analysis of LDL oxidation
2.5.1. Conjugated dienes (CD). Prior to the estimation of CD,
100 Wl of the respective LDL sample was applied to small Sephadex
columns (Nick columns, Pharmacia) equilibrated in 0.025 mol/l phos-
phate bu¡er pH 7.4 to get rid of low molecular weight compounds.
Absorbance of the samples was read at 234 nm. The CD concentra-
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tion was calculated using a molar extinction coe⁄cient of O=
2.95U104 M31 cm31 [23].
2.5.2. Thiobarbituric acid assay. LDL oxidation products were as-
sayed as TBARS as reported [21].
2.5.3. Lipid hydroperoxide assay. Lipid hydroperoxides were as-
sayed based on the method of El Saadani et al. [24] as modi¢ed by
Wallin and Camejo [25]. The concentration of hydroperoxides was
calculated from the molar absorption coe⁄cient of O= 2.46U104
M31 cm31 at 365 nm. Prior to the estimation of lipid hydroperoxides,
the LDL samples were applied to small Sephadex columns (Nick
columns, Pharmacia) equilibrated in 0.025 mol/l phosphate bu¡er
pH 7.4 to get rid of interfering low molecular weight compounds [20].
2.6. Lipid electrophoresis
Aliquots (10 Wl) of treated or untreated LDL were applied to agar-
ose gels (1% in veronal bu¡er) and run for 90 min, and lipoproteins
were detected according to the supplier of the analytical system (Lip-
idophor All In, Immuno-Baxter AG). Measurement of relative elec-
trophoretic mobility (REM) was taken as an indicator of LDL oxi-
dation [23], setting the electrophoretic mobility of native (untreated)
LDL arbitrarily as one.
2.7. Tissue factor (TF), clotting assay
Con£uent HUVEC cultures grown in 6-well plates were washed
with RPMI 1640 and treated for 4 h with the respective LDL prep-
arations (100 Wg/ml medium) to stimulate TF production [26]. Prior to
the addition of the treated LDL to the cells, low molecular weight
compounds were removed by gel ¢ltration on small Sephadex col-
umns. At the end of incubation, cells were washed with phosphate-
bu¡ered saline (PBS). HUVEC were scrape-harvested into 1 ml of
PBS and sonicated by a cell disrupter for 1 min at 4‡C. The lysate
was assayed in a one-stage clotting assay: 100 Wl citrated normal
donor platelet poor plasma was incubated for 1 min with 100 Wl
cell lysate at 37‡C in prewarmed plastic tubes of a KC-10 coagulom-
eter (Amelung, Germany); 100 Wl CaCl2 (30 mmol/l) was then added
and coagulation time was measured. Control experiments with factor
VII, IX and X de¢cient plasma (Behring, Germany) characterised the
procoagulant activity as TF [22].
2.8. Spectroscopy
Stock solutions of salicylate, 2,3-DHBA or 2,5-DHBA and ions
(Fe2 as (NH4)2Fe(SO4)2W6H2O, Fe3 as FeCl3W6H2O) were mixed
to give a ¢nal concentration of 200 Wmol/l in 0.15 mol/l sodium chlo-
ride with or without 10 mmol/l phosphate bu¡er (or Tris^HCl) pH
7.4. Spectra were recorded between 700 and 220 nm.
3. Results
To examine the potential of aspirin and its pharmacological
metabolites, salicylate and gentisic acid to prevent the oxida-
tive (atherogenic) modi¢cation of LDL by the various reactive
oxygen species generated by glucose autoxidation [16,17],
LDL (1 mg/ml) was incubated in the presence of glucose
(200 mmol/l) [7,15] with or without the respective compound.
As can be seen in Fig. 1A, when LDL was incubated with
glucose for 4 days at 37‡C, both 2,3- and 2,5-DHBA reduced
CD formation in a concentration dependent manner. Neither
the parent drug aspirin nor the ¢rst line metabolite salicylate
had any in£uence on LDL oxidation. Parallel estimation of
other parameters of lipid peroxidation (lipid hydroperoxides
(Fig. 1B) and TBARS formation (Fig. 1C)) showed similar
results. 20^50 Wmol/l of 2,3- or 2,5-DHBA suppressed lipid
hydroperoxide production and TBARS formation.
TF can be induced in endothelial cells by oxidised LDL
[26,27]. When LDL (1 mg/ml) was incubated in the presence
of glucose (200 mmol/l) for 9 days at 37‡C and subsequently
HUVEC cultures were treated with this LDL preparation
(100 Wg/ml medium) for 4 h, TF was induced as assessed by
a clotting assay (see Section 2). TF induction could be pre-
vented if 2,3- or 2,5-DHBA were present during glucose-medi-
ated LDL oxidation. Aspirin and salicylate again had no in-
£uence in this system.
The very di¡erent ability of the compounds to overcome the
e¡ect of glucose treatment on LDL in respect to TF induction
in HUVEC cultures was also re£ected in their antioxidant
Fig. 1. In£uence of aspirin, salicylate, 2,5-DHBA and 2,3-DHBA on
glucose-mediated LDL oxidative modi¢cation. LDL (1 mg/ml) was
incubated in 0.1 mol/l phosphate bu¡er pH 7.4 for 4 days at 37‡C
in the presence of glucose (200 mmol/l) and the respective com-
pound. At the end of incubation, 100 Wl sample was applied to
Sephadex columns to get rid of low molecular weight compounds
and subsequently CD (A) and lipid hydroperoxides (B) were esti-
mated in aliquots of the eluted lipoprotein fraction. TBARS (C)
were estimated in an aliquot of the incubation mixtures. The dotted
line represents levels of CD, lipid hydroperoxides and TBARS in
LDL preparations without glucose.
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potential under these LDL/glucose preincubation conditions
(9 days at 37‡C, see Fig. 2, inset).
Glycated LDL has been shown to be more prone to oxida-
tion than unmodi¢ed LDL [15]. Thus, the DHBA derivatives
may inhibit LDL glycation resulting in less LDL oxidation by
glucose. Incubation of LDL with [14C]glucose (see Section 2)
resulted in the binding of 13.7 þ 0.87 nmol glucose/mg LDL
(n = 2). Neither 2,3- nor 2,5-DHBA (molar ratio glucose/com-
pound = 400) inhibited LDL glycation (14.1 þ 1.51 and
14.0 þ 1.32 nmol glucose/mg LDL, respectively) (n = 2). Aspir-
in and salicylate were also ine¡ective.
Metal ions can catalyse glucose oxidation [14^17]. Binding
of such ions may result in inhibition of LDL oxidation. Spec-
tral analysis revealed that salicylate, 2,3- and 2,5-DHBA
formed violet complexes (absorption maxima 526, 575 and
612 nm, respectively) with Fe3 but not Fe2 in unbu¡ered
sodium chloride solution. However, in the presence of phos-
phate ions, the Fe3 complexes were not formed. In contrast
to salicylate and 2,5-DHBA in phosphate (or Tris^HCl)-bu¡-
ered (pH 7.4) solution, 2,3-DHBA formed a coloured chelate
with Fe2. Thus under the conditions of the LDL oxidation
system (phosphate bu¡er), metal chelation may be limited to
2,3-DHBA only.
4. Discussion
The autoxidation of glucose generates a battery of reactive
products like superoxide, hydroxyl, hydroxyalkyl and peroxyl
radicals and hydrogen peroxide [16,17,28]. LDL exposed to
glucose in vitro is known to undergo glycation and peroxida-
tion of the apoprotein and lipid moiety, respectively [13^15].
These modi¢cations result in a lipoprotein particle known to
initiate and support atherogenic events [29^31].
Taken all these observations into account, antioxidative
compounds [32,33] may have bene¢cial e¡ects regarding dia-
betic complications like atherosclerosis. Salicylate has been
shown to scavenge particular radical species and salicylate
hydroxylation resulting in 2,3-DHBA formation has been im-
plicated as an indicator of hydroxyl radicals produced and
involved in certain diseases as e.g. arthritis [18,19]. We now
show that the second line aspirin metabolite gentisic acid ef-
fectively counteracted the oxidative modi¢cation of LDL by
Fig. 2. In£uence of glucose-oxidised LDL on TF coagulant activity in human endothelial cells. LDL (1 mg/ml) was preincubated in 0.1 mol/l
phosphate bu¡er pH 7.4 for 9 days at 37‡C in absence or presence of glucose (200 mmol/l) and the respective compound (500 Wmol/l). At the
end of incubation, 100 Wl sample was applied to Sephadex columns to get rid of low molecular weight compounds and subsequently, HUVEC
cultures were exposed for 4 h to the respective LDL preparations (100 Wg/ml medium). Cells were washed with PBS and the TF coagulant ac-
tivity was estimated in aliquots of HUVEC protein extracts as given under Section 2. Inset: TBARS (right axis/black columns) and REM (left
axis/empty columns) in the respective LDL preincubations.
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the battery of glucose autoxidation-derived radicals. However,
the parent drug salicylate as well as aspirin were not able to
prevent glucose-mediated LDL oxidation. In contrast, salicy-
late has been found to protect LDL from oxidation by super-
oxide/nitric oxide radicals [20] and aspirin inhibited LDL oxi-
dation by UV irradiation initiated radical reactions [34].
Our results show that both DHBA compounds do not act
via reduced LDL glycation which may result in lower suscep-
tibility of LDL to oxidative modi¢cation. Another possible
mechanism of inhibiting glucose-mediated LDL oxidation by
2,3- or 2,5-DHBA may be the ability to complex transition
metal ions. For some phenolics, it has been proposed and
demonstrated that they scavenge catalytically active metal
ions [35]. Our results show that 2,3-DHBA was able to com-
plex Fe2 and thus the compound may exert its antioxidative
potential, at least partially, by this mechanism. On the other
hand, 2,5-DHBA mainly acts as a free radical scavenger under
these conditions. It should be mentioned that salicylate was
not found to inhibit the transition metal ion-promoted LDL
oxidation [36].
The present results were obtained at glucose/gentisic acid
ratios (mol/mol) of 8000 and 400. In humans plasma, levels of
2 mmol/l salicylate, which can be reached under aspirin ther-
apy, lead to levels of about 20 Wmol/l gentisic acid [37]. Thus
in normoglycemic individuals assuming a plasma glucose con-
centration of 4^6 mmol/l, the molar ratio of glucose/gentisic
acid may be 160^240. In the present in vitro system, gentisic
acid at molar ratios of 400^8000 inhibited the oxidative mod-
i¢cation of LDL by glucose. Thus one may speculate that in
vivo, the compound may also be able to protect LDL from
glucose oxidative reaction products generated in hyperglycae-
mia.
In summary, our results show that the pharmacological
(2,5-DHBA) and pathophysiological (2,3-DHBA) salicylate
metabolite but not the parent drug was an e⁄cacious antioxi-
dant in respect to LDL modi¢cation by glucose autoxidative
radical reaction products, potently inhibiting the formation of
atherogenic LDL particles at glucose/gentisic acid molar ra-
tios which may also be found in vivo, further supporting the
rationale for prophylactic aspirin medication [38,39] against
vascular complications.
References
[1] Baynes, J.W. and Thorpe, S.R. (1999) Diabetes 48, 1^9.
[2] Karpen, C.W., Cataland, S., O’Dorisio, T.M. and Panganamala,
R.V. (1984) Diabetes 33, 239^243.
[3] Som, S., Basu, S., Mukherjee, D., Deb, S., Choudhury, P.R.,
Mukherjee, S., Chatterjee, S.N. and Chatterjee, I.B. (1981) Me-
tabolism 30, 572^577.
[4] Brownlee, M., Cerami, A. and Vlassara, H. (1988) N. Engl. J.
Med. 318, 1315^1321.
[5] Bucala, R. and Cerami, A. (1992) Adv. Pharmacol. 23, 1^34.
[6] Schleicher, E., Deufel, T. and Wieland, O.H. (1981) FEBS Lett.
129, 1^4.
[7] Bucala, R., Makita, Z., Koschinsky, T., Cerami, A. and Vlassara,
H. (1993) Proc. Natl. Acad. Sci. USA 90, 6434^6438.
[8] Berg, T.J., Nourooz Zadeh, J., Wol¡, S.P., Tritschler, H.J.,
Bangstad, H.J. and Hanssen, K.F. (1998) Diabetes Care 21,
1295^1300.
[9] Laakso, M. (1999) Diabetes 48, 937^942.
[10] Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C. and
Witztum, J.L. (1989) N. Engl. J. Med. 320, 915^924.
[11] Steinberg, D. (1997) J. Biol. Chem. 272, 20963^20966.
[12] Steinberg, D. (1997) Circulation 95, 1062^1071.
[13] Witztum, J.L., Mahoney, E.M., Branks, M.J., Fisher, M., Elam,
R. and Steinberg, D. (1982) Diabetes 31, 283^291.
[14] Hunt, J.V., Smith, C.C. and Wol¡, S.P. (1990) Diabetes 39,
1420^1424.
[15] Millican, S.A., Schultz, D., Bagga, M., Coussons, P.J., Muller,
K. and Hunt, J.V. (1998) Free Radic. Res. 28, 533^542.
[16] Wol¡, S.P. and Dean, R.T. (1987) Biochem. J. 245, 243^250.
[17] Wol¡, S.P., Jiang, Z.Y. and Hunt, J.V. (1991) Free Radic. Biol.
Med. 10, 339^352.
[18] Kaur, H., Whiteman, M. and Halliwell, B. (1997) Free Radic.
Res. 26, 71^82.
[19] Grootveld, M. and Halliwell, B. (1986) Biochem. J. 237, 499^504.
[20] Hermann, M., Kapiotis, S., Hofbauer, R., Exner, M., Seelos, C.,
Held, I. and Gmeiner, B. (1999) FEBS Lett. 445, 212^214.
[21] Hermann, M. and Gmeiner, B. (1992) Arterioscler. Thromb. 12,
1503^1506.
[22] Kapiotis, S., Besemer, J., Bevec, D., Valent, P., Bettelheim, P.,
Lechner, K. and Speiser, W. (1991) Blood 78, 410^415.
[23] Esterbauer, H., Striegl, G., Puhl, H. and Rotheneder, M. (1989)
Free Radic. Res. Commun. 6, 67^75.
[24] el Saadani, M., Esterbauer, H., el Sayed, M., Goher, M., Nassar,
A.Y. and Jurgens, G. (1989) J. Lipid Res. 30, 627^630.
[25] Wallin, B. and Camejo, G. (1994) Scand. J. Clin. Lab. Invest. 54,
341^346.
[26] Drake, T.A., Hannani, K., Fei, H.H., Lavi, S. and Berliner, J.A.
(1991) Am. J. Pathol. 138, 601^607.
[27] Fei, H., Berliner, J.A., Parhami, F. and Drake, T.A. (1993) Arte-
rioscler. Thromb. 13, 1711^1717.
[28] Jiang, Z.Y., Woollard, A.C. and Wol¡, S.P. (1990) FEBS Lett.
268, 69^71.
[29] Simionescu, M. and Simionescu, N. (1993) FASEB J. 7, 1359^
1366.
[30] Berliner, J.A., Navab, M., Fogelman, A.M., Frank, J.S., Demer,
L.L., Edwards, P.A., Watson, A.D. and Lusis, A.J. (1995) Cir-
culation 91, 2488^2496.
[31] Berliner, J.A. and Heinecke, J.W. (1996) Free Radic. Biol. Med.
20, 707^727.
[32] Heinecke, J.W. (1998) Atherosclerosis 141, 1^15.
[33] Morel, D.W. and Chisolm, G.M. (1989) J. Lipid Res. 30, 1827^
1834.
[34] Steer, K.A., Wallece, T.M., Bolton, C.H. and Hartog, M. (1997)
Heart 77, 333^337.
[35] Miller, N.J., Castelluccio, C., Tijburg, L. and Rice-Evans, C.
(1996) FEBS Lett. 392, 40^44.
[36] Bolton, C.H., Dwight, J., Hopton, M.I., Steer, K. and Hartog,
M. (1997) Biochem. Soc. Trans. 25, 521S.
[37] Forth, W., Henschler, D. and Rummel, W. (1987) Allgemeine
und spezielle Pharmakologie und Toxikologie, Wissenschaftsver-
lag, Mannheim.
[38] Fuster, V., Dyken, M.L., Vokonas, P.S. and Hennekens, C.
(1993) Circulation 87, 659^675.
[39] Ranke, C., Hecker, H., Creutzig, A. and Alexander, K. (1993)
Circulation 87, 1873^1879.
FEBS 23430 9-3-00
M. Exner et al./FEBS Letters 470 (2000) 47^5050
